4Cyte Pathology

Name

4Cyte Pathology

Website

https://4cyte.com.au

Company type

Private

Founded year

2018

Headcount range

11–50 employees

Short description

4Cyte Pathology is an Australian independent specialist pathology laboratory founded in 2018 and headquartered in Ryde, NSW, providing diagnostic testing services to the Australian healthcare market via GP and specialist referrals.

Ownership category

akta.pro rank

Product category

Diagnostic Pathology Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Anatomic Pathology (Histopathology & Cytopathology) (HLAFAMAA)

akta.pro secondary industry

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• Pathology diagnostics
• Medical laboratory testing
• Clinical pathology services
• Diagnostic testing services
• Anatomical pathology

Headquarters

HQ city

Ryde

HQ country

Australia

HQ region

Oceania

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D

Core offering

4Cyte Pathology is an independent specialist medical laboratory that provides diagnostic pathology testing services to patients across Australia. The company receives patient specimens referred by general practitioners and medical specialists and processes them in its laboratories to deliver diagnostic results that inform clinical decision-making.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Direct peers

• Australian Clinical Labs: ASX-listed pathology operator (ACL) running a national network of collection centres and laboratories across Australia. Closest direct comparable to 4Cyte in service mix, customer base (GPs/specialists/hospitals), and geographic market.
• Sonic Healthcare: ASX-listed global pathology and radiology operator and the dominant Australian pathology network (Sullivan Nicolaides, Douglass Hanly Moir, Melbourne Pathology, etc.). Direct competitor for GP-referred work, with substantially larger scale and IT infrastructure.
• Healius: ASX-listed operator of one of Australia's three major pathology networks (QML, Laverty, Dorevitch, Western Diagnostic Pathology). Direct competitor targeting the same GP-referred and specialist workflow as 4Cyte.
• Capital Pathology: ACT and surrounds pathology provider operating collection centres and a central lab; comparable in service mix and GP-referral model, useful benchmark for a regional Australian pathology operator.
• Clinipath Pathology: Western Australian pathology provider offering routine and specialist pathology to GPs and specialists. Comparable scope of services and customer base to 4Cyte, with similar regional-network economics.

Emerging players

• Histopath Diagnostic Specialists: Independent specialist histopathology laboratory in Australia focused on skin and tissue diagnostics. Comparable independent-specialist positioning to 4Cyte and useful proxy for the niche-lab economics 4Cyte targets.
• SDx (Specialist Diagnostic Services): Australian specialist pathology provider focused on dermatopathology and women's health screening. Comparable independent-specialist positioning, niche sub-segment focus, and Australian geographic footprint to 4Cyte.

Broad incumbents

• Quest Diagnostics: US-listed global clinical laboratory and diagnostics giant. Comparable core business (anatomic and clinical pathology, esoteric testing) and useful for international benchmark on unit economics, even though not a direct Australian competitor.
• Laboratory Corporation of America (Labcorp): US-listed global clinical laboratory operator with extensive anatomic pathology and specialty testing menu. Comparable core lab-services offering and useful international benchmark for independents scaling specialty menus.

Regional players

• Virtus Health: ASX-listed Australian specialty diagnostics and fertility services operator. Not a pure pathology peer, but comparable as a specialist Australian diagnostics operator with adjacent service lines and similar regulatory/operating environment.

Market position

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 4Cyte Pathology